Dual Therapeutic Utility of Proteasome Modulating Agents for Pharmaco-gene Therapy of the Cystic Fibrosis Airway
Open Access
- 1 December 2004
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 10 (6) , 990-1002
- https://doi.org/10.1016/j.ymthe.2004.08.009
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Distinct Classes of Proteasome-Modulating Agents Cooperatively Augment Recombinant Adeno-Associated Virus Type 2 and Type 5-Mediated Transduction from the Apical Surfaces of Human Airway EpitheliaJournal of Virology, 2004
- A sensitive, real-time, RNA-specific PCR method for the detection of recombinant AAV-CFTR vector expressionGene Therapy, 2003
- Phase I Trial of Intranasal and Endobronchial Administration of a Recombinant Adeno-Associated Virus Serotype 2 (rAAV2)-CFTR Vector in Adult Cystic Fibrosis Patients: A Two-Part Clinical StudyHuman Gene Therapy, 2003
- Second-Strand Genome Conversion of Adeno-Associated Virus Type 2 (AAV-2) and AAV-5 Is Not Rate Limiting following Apical Infection of Polarized Human Airway EpitheliaJournal of Virology, 2003
- ENaC Degradation in A6 Cells by the Ubiquitin-Proteosome Proteolytic PathwayJournal of Biological Chemistry, 2001
- Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virusJournal of Clinical Investigation, 2000
- Identification of the Cystic Fibrosis Transmembrane Conductance Regulator Domains That Are Important for Interactions with ROMK2Journal of Biological Chemistry, 2000
- Polarity Influences the Efficiency of Recombinant Adenoassociated Virus Infection in Differentiated Airway EpitheliaHuman Gene Therapy, 1998
- Cystic Fibrosis Airway Epithelia Fail to Kill Bacteria Because of Abnormal Airway Surface FluidCell, 1996
- A Pilot Study of Aerosolized Amiloride for the Treatment of Lung Disease in Cystic FibrosisNew England Journal of Medicine, 1990